Latest filing published 24 Feb 2023 for Voyager Therapeutics, Inc., €36.8M.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +20.7%Entry US$7.16 · Close at T+365 US$8.64
- -65.4%Entry US$19.66 · Close at T+365 US$6.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Neurocrine Biosciences Inc: trading record in brief
Neurocrine Biosciences Inc discloses dealings in Voyager Therapeutics, Inc. to SEC (Form 4). The record holds 2 filings, for trades running from 12 March 2019 to 23 February 2023.
The open-market record is one-sided, with 2 purchases worth €81.2M and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2023, the count stands at 1 purchase and no sales.
The latest filing, published on 24 February 2023, reports an open-market purchase of €36.8M in Voyager Therapeutics, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Neurocrine Biosciences Inc
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,395,588 shares@ US$8.88100.0% of flowCommon StockSEC:0000899243-23-006093:0Canonical exit: 24 May 2023 (T+90)
- 4,179,728 shares@ US$11.9654.7% of flowCommon StockSEC:0001209191-19-019459:0Canonical exit: 10 Jun 2019 (T+90)
2 of 2 declarations
